|1.||Goodman, William G: 22 articles (07/2015 - 04/2002)|
|2.||Chertow, Glenn M: 16 articles (12/2015 - 10/2005)|
|3.||Block, Geoffrey A: 15 articles (07/2015 - 11/2003)|
|4.||Fukagawa, Masafumi: 15 articles (01/2013 - 05/2004)|
|5.||Floege, Jürgen: 14 articles (07/2015 - 09/2007)|
|6.||Moe, Sharon M: 12 articles (07/2015 - 01/2003)|
|7.||Nagano, Nobuo: 11 articles (10/2012 - 06/2003)|
|8.||Parfrey, Patrick S: 10 articles (12/2015 - 07/2012)|
|9.||Dehmel, Bastian: 10 articles (12/2015 - 06/2010)|
|10.||Drüeke, Tilman B: 10 articles (07/2015 - 04/2004)|
11/01/2003 - "Recently completed phase 2 clinical trials with the second-generation calcimimetic agent cinacalcet HCl confirm that this agent represents a safe and effective novel therapeutic agent which has the potential to dramatically alter the treatment and complications associated with secondary hyperparathyroidism in patients on dialysis."
07/01/2009 - "Secondary hyperparathyroidism (SHPT) is a relevant problem in patients undergoing dialysis, and cinacalcet hydrochloride seems to be the best option for controlling it. "
09/01/2013 - "Although secondary hyperparathyroidism tended to be more severe in our Dutch cohort, compared with the entire ECHO cohort, cinacalcet was nevertheless effective in reducing PTH in these patients. "
03/01/2013 - "Cinacalcet is effective for treating refractory secondary hyperparathyroidism (SHPT), but little is known about the response rates and clinical factors influencing the response. "
07/01/2009 - "Cinacalcet was effective in the management of posttransplant persistent secondary hyperparathyroidism, resulting in decreased calcemia and iPTH, while also improving femoral neck bone loss. "
02/01/2004 - "The present findings provide compelling evidence that cinacalcet HCl is a potent and stereoselective activator of the parathyroid CaR and, as such, might be beneficial in the treatment of hyperparathyroidism."
03/01/2015 - "At the end of the period of treatment with cinacalcet, for both variants of hyperparathyroidism, a statistically significant reduction in the overall number and in the diameter of renal stones was found. "
12/01/2010 - "Cinacalcet was effective in treating posttransplant hyperparathyroidism, resulting in decreased calcemia and transient decreased iPTH. "
03/01/2005 - "Cinacalcet HCl: a novel therapeutic for hyperparathyroidism."
11/27/2012 - "From nonrandomized studies, cinacalcet appears to be safe and effective for the treatment of posttransplant hyperparathyroidism. "
|3.||Hypercalcemia (Milk Alkali Syndrome)
11/01/2012 - "Cinacalcet was effective for long-term control of hypercalcemia related to persistent HPT for patients with stable KT."
06/01/2011 - "Cinacalcet has proved efficient in short- and long-term controls of hypercalcemia and, though bone mineral density was not improved, the available data point to cinacalcet as the treatment of choice in non-operable patients with pHPT. "
11/01/2012 - "We aimed to evaluate the long-term efficacy of cinacalcet in functioning stable KT subjects with hypercalcemia secondary to persistent HPT. "
01/01/2011 - "Three months after the initiation of cinacalcet treatment, all our patients experiencing clinical signs of hypercalcemia had improved in self -reported well-being and in biochemical parameters. "
07/01/2009 - "We sought to analyze the efficacy of treatment with cinacalcet for patients with hypercalcemia (Ca > 10.5 mg/dL) secondary to HPT. "
|4.||Kidney Diseases (Kidney Disease)
01/01/2013 - "Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials."
07/01/2015 - "[The use of Cinacalcet in chronic kidney disease: a case report]."
01/01/2015 - "Cinacalcet, a calcimimetic drug, has been shown to be efficacious in adult chronic kidney disease (CKD) patients; however, it was not fully studied in pediatric CKD patients. "
01/01/2015 - "Cinacalcet in pediatric and adolescent chronic kidney disease: a single-center experience."
04/01/2013 - "In addition, the subjects in the d-cinacalcet group had a greater proportion to achieve Kidney Disease Outcomes Quality Initiative (KDOQI)-recommended biochemical targets than the subjects in the VitD group (Ca: 48% vs. 24%; P: 78% vs. 32%; Ca × P: 85% vs. 37%; iPTH: 15% vs. 0%). "
01/01/2006 - "Clinical studies performed in primary hyperparathyroidism proved AMG 073 to be effective in reducing both PTH and Ca serum levels, with a good safety profile. "
06/01/2011 - "Cinacalcet is effective in controlling the biochemical abnormalities in patients with primary hyperparathyroidism (PHPT) but it seems to be less effective on bone mineral density (BMD). "
12/01/2014 - "The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice."
12/01/2009 - "Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study."
12/01/2003 - "In this randomized, double-blind, dose-finding study, patients (n = 22) with primary hyperparathyroidism were given cinacalcet (30, 40, or 50 mg) or placebo twice daily for 15 d and observed for an additional 7 d. "
|3.||Parathyroid Hormone (Parathormone)
|9.||Biological Markers (Surrogate Marker)
|1.||Renal Dialysis (Hemodialysis)
|5.||Transplantation (Transplant Recipients)